The role of B cell receptor clone test and Adiponectin as a predictors of rheumatoid arthritis
DOI:
https://doi.org/10.61841/hc5wjp35Keywords:
BCR, ADP, rheumatoid arthritis, biological treatment,, chemotherapy treatment.Abstract
Rheumatoid arthritis (RA) means chronic inflammatory sickness with systemic characteristics involving joints, leading to erosive synovitis, degradation of cartilage, and destruction of joints. The aim of this study was for assessment of serum levels of B Cell Receptor (BCR) clones and Adiponectin (ADP) in RA and the correlation between them in biological, chemotherapy, biological, and chemotherapeutic treatment strategies. Seventy eight individuals have included in this study, 60 patients (51 females and 9 males) with 18 control (13 female and 5 male). Patients with RA were diagnosed by a consultant rheumatologist according to ACR / EULAR criteria in 2010. They were divided into three groups; patients had biological treatment (bio.), chemotherapy (chem.), and biological and chemotherapy. Evaluation of the RA activity using Disease Activity Score 28 (DAS28) was done. Enzyme-linked immunosorbent assay (ELISA) was used to detect B Cell Receptor and Adiponectin. BCR clones, ADP were assessed. The results showed a highly significant increase (p= 0.0001) in the serum level of BCR observed in both biological group and biological and chemotherapy groups as compared to control. The ADP serum level had a highly significant increase (p= 0.002) in the biological group as compared with the control group. There was a significant Negative correlation between ADP with BCR level (P-Value=0.039) in patients who had biological treatment.
In conclusion, In patients who had biological treatment, there was a significant increase in serum BCR levels and ADP levels.
Downloads
References
1. Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., ... & Aletaha, D. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2016 update. Annals of the rheumatic diseases, 76(6), 960-977.
2. Pallinti, V., Ganesan, N., Anbazhagan, M., & Rajasekhar, G. (2009). Serum biochemical markers in rheumatoid arthritis.
3. Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham III, C. O., ... & Combe,
B. (2010). 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatism, 62(9), 2569-2581
4. Brown, P. M., Pratt, A. G., & Isaacs, J. D. (2016). Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nature Reviews Rheumatology, 12(12), 731-742.
5. Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018). Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone research, 6(1), 1-14.
6. Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A. & Coggeshall, M. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet, 388(10053), 1545-1602
7. Hutchinson, D., Shepstone, L., Moots, R., Lear, J. T., & Lynch, M. P. (2001). Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA. Annals of the rheumatic diseases, 60(3), 223-227.
8. Nigro, E., Scudiero, O., Monaco, M. L., Palmieri, A., Mazzarella, G., Costagliola, C., ... & Daniele,
A. (2014). New insight into adiponectin role in obesity and obesity-related diseases. BioMed research international, 2014.
9. Suresh, S., & Shetty, P. 2018. Naturopathic and Dietary Interventions in the Management of Rheumatoid Arthritis: A Case Study Report.
10. Tak, P. P., Doorenspleet, M. E., de Hair, M. J., Klarenbeek, P. L., van Beers-Tas, M. H., van Kampen,
A. H., ... & de Vries, N. (2017). Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis. Annals of the rheumatic diseases, 76(11), 1924- 1930
11. . Bucala, R. J., Solomon, D. H., Craft, J. E., Felson, D. T., Loeser Jr, R. F., Nigrovic, P. A., ... & Terkeltaub, R. (2019). Arthritis & Rheumatology
12. Lee, Y. H., & Bae, S. C. (2018). Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta analysis. International journal of rheumatic diseases, 21(3), 664-672.
13. Nagashima, T., Okubo-Fornbacher, H., Aoki, Y., Kamata, Y., Kimura, H., Kamimura, T., ... & Minota, S. (2008). Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. The Journal of Rheumatology, 35(5), 936- 938
14. Veluri, G., Vinapamula, K. S., Rao, P. V. S., Kommireddy, S., Manohar, S. M., & Pasupuleti, P. (2019). Serum adiponectin levels in patients with rheumatoid arthritis. Indian Journal of Rheumatology, 14(2), 119
15. El-Hini, S. H., Mohamed, F. I., Hassan, A. A., Ali, F., Mahmoud, A., & Ibraheem, H. M. (2013). Visfatin and adiponectin as novel markers for evaluation of metabolic disturbance in recently diagnosed rheumatoid arthritis patients. Rheumatology international, 33(9), 2283-2289
16. Šenolt, L., Pavelka, K., Housa, D., & Haluzik, M. (2006). Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine, 35(5-6), 247-252
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
